Press Releases For all investor or media inquiries, visit https://www.adaptimmune.com/contact. Year All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | Dec 21, 2020 TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference Dec 13, 2020 TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors Dec 11, 2020 TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors Nov 12, 2020 TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Nov 10, 2020 TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity Sep 29, 2020 TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit Sep 08, 2020 TCR² Therapeutics to Participate in Two Upcoming Conferences in September Aug 12, 2020 TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Aug 06, 2020 TCR² Therapeutics to Present at the Wedbush PacGrow Healthcare Conference Jul 28, 2020 TCR² Therapeutics Announces Pricing of Public Offering of Common Stock Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »